Impact – The Cone and Plate(let) Analyzer: Testing Platelet Function and Anti-Platelet Drug Response

Savion, Naphtali; Varon, David

doi:10.1159/000093548

Cited by 63 publications

(44 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CPA is a validated technique also for the assessment of shear stress-induced platelet aggregation [27]. Following shear stress average platelet aggregate size in control conditions equalled 38.28 ± 7.440 (n = 5) and decreased to 8.926 ± 0.4291 (n = 5, P = 0.0254) in DMSO treated samples (data not shown).…”

Section: Dmso Inhibits Platelet Adherencementioning

confidence: 93%

DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

Asmis

Tanner

Sudano

et al. 2010

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Section: Dmso Inhibits Platelet Adherencementioning

confidence: 93%

DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

Asmis

Tanner

Sudano

et al. 2010

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…One exception is the IMPACT cone and plate analyzer (CPA), which was developed to more accurately represent natural haemostasis. 16 In the CPA, a polystyrene plate is used to monitor platelet adhesion and aggregation in a well-defined shear environment. Plasma proteins are allowed to adsorb to the surface of a polystyrene plate from whole blood, creating a thrombogenic surface.…”

Section: Platelet Function Assaysmentioning

confidence: 99%

Functional assay of antiplatelet drugs based on margination of platelets in flowing blood

2016

View full text Add to dashboard Cite

A novel functional assay of antiplatelet drug efficacy was designed by utilizing the phenomena of platelet margination in flowing blood and transient platelet contacts with surface-immobilized platelet agonists. Flow margination enhances transient contacts of platelets with the walls of flow chambers covered with surface-immobilized proteins. Depending on the type and the surface density of the immobilized agonists, such transient interactions could "prime" the marginated platelet subpopulation for enhanced activation and adhesion downstream. By creating an upstream surface patch with an immobilized platelet agonist, platelet flow margination was used to test how effective antiplatelet drugs are in suppressing downstream platelet activation and adhesion. The platelet adhesion downstream was measured by a so-called "capture" patch region close to the distal end of the flow chamber. Platelet adhesion downstream was found to be dose-dependent on the upstream surface coverage of the "priming" patch, with immobilized fibrinogen acting as a platelet agonist. Several antiplatelet agents (acetylsalicylic acid, eptifibatide, and tirofiban) were evaluated for their efficacy in attenuating downstream adhesion after upstream platelet priming. The activation of the platelet population was found to be dependent on both the extent of the upstream agonist stimulus and the antiplatelet drug concentration. Such a relationship provides an opportunity to measure the efficacy of specific antiplatelet agents against the type and concentration of upstream platelet agonists.

show abstract

“…Platelet secretion and aggregation tests provide evidence for defects, but these parameters are not universally predictive of the severity of bleeding symptoms. The cone and plate(let) analyser (Impact) may be useful to analyse platelet adhesion (see above) and subsequent platelet aggregation on different adhesive substrates under different shear conditions [117]. In contrast to other global tests, also hyperreactivity of platelets is reflected when using this device.…”

Section: Approach To Diagnosismentioning

confidence: 99%

Inherited and Acquired Disorders of Platelet Function

Jurk

Kehrel²

2007

Transfus Med Hemother

View full text Add to dashboard Cite

Platelet function defects are caused by rare congenital or, more frequently, by acquired disorders. They may lead to bleeding or thrombotic tendencies despite of normal platelet counts. The corresponding symptoms are often quite heterogeneous. A disorder of platelet function is suspected on the basis of case and family history, physical examination and platelet function tests. The so far primary screen of platelet dysfunctions, the bleeding time, is neither very sensitive nor specific and depends very much on the skills of the person that performs the test. Therefore, other general and in addition more specialised laboratory tests have to be performed for diagnosing an isolated platelet abnormality or in most cases combined platelet function defects. An approach to diagnosing a platelet disorder is presented, which supports the high significance of flow cytometry in platelet function analysis. Furthermore, we like to elucidate that in most cases a platelet-mediated haemostatic disorder cannot be characterised by just a single function defect, but rather by a combination of platelet functional abnormalities. Detailed knowledge of the platelet disorder is necessary for adequate therapeutical management of the individual patient, including the control of the underlying disease in acquired disorders, transfusion of platelets and administration of haemostatic drugs.

show abstract

Impact – The Cone and Plate(let) Analyzer: Testing Platelet Function and Anti-Platelet Drug Response

Cited by 63 publications

References 22 publications

DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?

Functional assay of antiplatelet drugs based on margination of platelets in flowing blood

Inherited and Acquired Disorders of Platelet Function

Contact Info

Product

Resources

About